HPB : the official journal of the International Hepato Pancreato Biliary Association · 2025
Enhancing management of pancreatic cancer: impact of a same day multidisciplinary clinic on access to guideline-directed care.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ebia Matthew I, Abbas Anser A, Levi Abrahm, Davelaar John, Rosenberg Elissa, Atkins Katelyn M, Kamrava Mitchell, Lo Simon, Gaddam Srinivas, Gangi Alexandra, Kosari Kambiz, Arora Arpit, Haladjian Nanor, Laszlo Meghan, Oppenheim Steven, Reckamp Karen L, Nissen Nicholas, Larson Brent K, Wachsman Ashley, Gong Jun, Ferrone Cristina, Hendifar Andrew E, Osipov Arsen
Аннотация
BACKGROUND: Pancreatic cancer (PC) requires a multimodal treatment approach. We evaluated the impact of our same-day pancreatic multidisciplinary clinic (PMDC) on genetic testing, ancillary service access, treatment timelines, clinical trial enrollment, and survival.
METHODS: We retrospectively compared guideline directed care, clinical metrics and outcomes in patients managed through our PMDC (n = 87; Oct 2021-June 2023) versus an age- and resectability-matched cohort from our internal registry who received standard sequential care non-PMDC (n = 87; Jan-Dec 2020).
RESULTS: PMDC patients were significantly more likely to undergo somatic (OR 3.69, p < 0.001) and germline testing (OR 15.41, p < 0.001), receive upfront access palliative care (OR 7.86, p < 0.001) and social services (OR 4.48, p = 0.028), initiate treatment sooner (14.3 vs. 30.9 days, p = 0.002), and enroll in clinical trials (OR 2.30, p = 0.042). Among newly diagnosed metastatic PC patients, PMDC care was independently associated with improved survival (487 vs. 267 days, p = 0.021).
CONCLUSION: A same-day PMDC significantly improves access to guideline-recommended care and prolongs survival in patients with metastatic pancreatic cancer.
METHODS: We retrospectively compared guideline directed care, clinical metrics and outcomes in patients managed through our PMDC (n = 87; Oct 2021-June 2023) versus an age- and resectability-matched cohort from our internal registry who received standard sequential care non-PMDC (n = 87; Jan-Dec 2020).
RESULTS: PMDC patients were significantly more likely to undergo somatic (OR 3.69, p < 0.001) and germline testing (OR 15.41, p < 0.001), receive upfront access palliative care (OR 7.86, p < 0.001) and social services (OR 4.48, p = 0.028), initiate treatment sooner (14.3 vs. 30.9 days, p = 0.002), and enroll in clinical trials (OR 2.30, p = 0.042). Among newly diagnosed metastatic PC patients, PMDC care was independently associated with improved survival (487 vs. 267 days, p = 0.021).
CONCLUSION: A same-day PMDC significantly improves access to guideline-recommended care and prolongs survival in patients with metastatic pancreatic cancer.